<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02634788</url>
  </required_header>
  <id_info>
    <org_study_id>INS005-15-062</org_study_id>
    <nct_id>NCT02634788</nct_id>
  </id_info>
  <brief_title>Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain</brief_title>
  <official_title>A Phase 3, Randomized, Double Blind, Multiple Dose, Parallel Group, Placebo Controlled Study of Buprenorphine Sublingual Spray (0.5 mg TID, 0.25 mg TID, and 0.125 mg TID) for the Treatment of Moderate to Severe Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>INSYS Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>INSYS Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to evaluate analgesic efficacy of Buprenorphine
      Sublingual (under the tongue) Spray compared with placebo in participants with postoperative
      pain after bunionectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2016</start_date>
  <completion_date type="Actual">June 24, 2016</completion_date>
  <primary_completion_date type="Actual">June 24, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric Rating Scale (NRS) Summed Pain Intensity Difference (SPID) Over 0 to 48 Hours After Time 0 (NRS SPID-48)</measure>
    <time_frame>Baseline and 0 to 48 hours after Time 0</time_frame>
    <description>Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug) and at multiple time points up to 48 hours after Time 0 (administration of first dose of study drug). Pain intensity difference is calculated by subtracting the pain intensity at each time point from the pain intensity at Time 0. The SPID scores are the sum of the differences at each time point multiplied by the duration in hours since the previous time point. Positive numbers indicate a reduction in pain [maximum(max)=10 at each time point], and negative numbers indicate an increase in pain [minimum(min)=-10 at each time point]. The overall min and max are -10 and 10 times the number of hours specified; SPID-48 range is -480 to 480. The NRS SPID-48 was analyzed using an analysis of covariance (ANCOVA) model, which included treatment and site as main effects and Baseline pain intensity as the covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NRS Mean Pain Intensity Difference (PID) at 4, 8, 24 and 48 Hours After Time 0</measure>
    <time_frame>Baseline and 4, 8, 24 and 48 hours after Time 0</time_frame>
    <description>Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug administration) and at multiple time points up to 48 hours after Time 0 (time of administration of the first dose of study drug). NRS PID is defined as the difference in pain at each scheduled timepoint relative to Baseline (PID=pain intensity at baseline - pain intensity at time point). A higher value of NRS PID score indicates a higher decrease in pain from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS Mean Pain Intensity Score at 4, 8, 24 and 48 Hours After Time 0</measure>
    <time_frame>4, 8, 24 and 48 hours after Time 0</time_frame>
    <description>Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug administration) and at multiple time points up to 48 hours after Time 0 (time of administration of the first dose of study drug). A lower value indicates improvement in pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS SPID Over 4 Hours (SPID-4), 8 Hours (SPID-8) and 24 Hours (SPID-24) After Time 0</measure>
    <time_frame>Baseline and 0 to 4, 0 to 8 and 0 to 24 hours after Time 0</time_frame>
    <description>Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug) and at multiple time points up to 48 hours after Time 0 (administration of first dose of study drug). Pain intensity difference is calculated by subtracting the pain intensity at each time point from the pain intensity at Time 0. The SPID scores are the sum of the differences at each time point multiplied by the duration in hours since the previous time point. Positive numbers indicate a reduction in pain [max=10 at each time point] and negative numbers indicate an increase in pain [min=-10 at each time point]. The overall min and max are -10 and 10 times the number of hours specified: SPID-4=(-40 to 40), SPID-8=(-80 to 80) and SPID-24=(-240 to 240). The NRS SPID-4, 8 and 24 were analyzed using an ANCOVA model which included treatment and site as main effects and Baseline pain intensity as the covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Pain Relief (TOTPAR) Over 4, 8, 24 and 48 Hours After Time 0</measure>
    <time_frame>4, 8, 24 and 48 hours after Time 0</time_frame>
    <description>TOTPAR was assessed by the participant using a 5-point NRS (0=no relief, 1=a little, 2=some, 3=a lot, 4=complete relief). TOTPAR scores were collected at Baseline (prior to study drug) and at multiple time points up to 48 hours after Time 0 (first dose of study drug). The TOTPAR scores are the sum of the pain relief at each time point multiplied by the duration in hours since the previous time point. Larger positive numbers indicate more pain relief (maximum=4 at each time point) and smaller positive numbers indicate less pain relief (minimum=0 at each time point). The overall minimum is 0 for each variable and the overall maximum is 4 times the number of hours specified for the variable: TOTPAR-4=(0 to 16), TOTPAR-8=(0 to 32), TOTPAR-24=(0 to 96) and TOTPAR-48=(0 to 192). TOTPAR-4, TOTPAR-8, TOTPAR-24 and TOTPAR-48 were analyzed using an ANCOVA model with factors for treatment, site and baseline pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Analgesia</measure>
    <time_frame>From Time 0 (first dose of study drug) to time of confirmed meaningful pain relief (up to 64 minutes)</time_frame>
    <description>Time to onset of analgesia was measured as time to first perceptible pain relief confirmed by meaningful pain relief using the 2-stopwatch method. The study staff started 2 stopwatches as soon as the first dose of study drug was administered. Each participant was instructed to stop the first stopwatch when he or she experienced any perceptible pain relief and the second stopwatch when he or she experienced pain relief that was meaningful to them. If the second stopwatch was not stopped, time was censored at the time of the second dose of study drug or the use of rescue medication, whichever came first. If both stopwatches were not stopped time was censored at the time of the second dose of study drug or the use of rescue medication whichever came first. Time to onset of analgesia was defined as the time when the first stopwatch was stopped given that the second stopwatch is stopped.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Scores in Each Pain Relief Category at 4, 8, 24 and 48 Hours After Time 0</measure>
    <time_frame>4, 8, 24 and 48 hours after Time 0 (first dose of study drug)</time_frame>
    <description>Pain relief was assessed by the participant using a 5-point NRS (0=no relief, 1=a little, 2=some, 3=a lot, 4=complete relief). The percentage of participants with scores in each pain relief category are reported. Missing values were imputed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Peak Scores in Each Pain Relief Category</measure>
    <time_frame>From Time 0 (first dose of study drug) up to 48 hours</time_frame>
    <description>Peak pain relief is the highest value of pain relief experienced during the study. Pain relief was assessed by the participant using a 5-point NRS (0=no relief, 1=a little, 2=some, 3=a lot, 4=complete relief). The percentage of participants with peak scores in each pain relief category are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Pain Relief</measure>
    <time_frame>From Time 0 (first dose of study drug) to time of peak pain relief (up to 1437 minutes)</time_frame>
    <description>Time to peak pain relief is the time to the highest value of pain relief experienced during the study. Pain relief was assessed by the participant using a 5-point NRS (0=no relief, 1=a little, 2=some, 3=a lot, 4=complete relief). If no pain relief was observed, then the time was censored at the time of the last pain assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Perceptible Pain Relief</measure>
    <time_frame>From Time 0 (first dose of study drug) to time of first perceptible pain relief (up to 83 minutes)</time_frame>
    <description>Time to first perceptible pain relief was evaluated using the 2 stopwatch method and is defined as the time when the participant stops the first stopwatch. If it was not stopped time was censored at the time that the second stopwatch was stopped or the time of the second dose or the time that rescue medication was used whichever came first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Meaningful Pain Relief</measure>
    <time_frame>From Time 0 (first dose of study drug) to time of meaningful pain relief (up to 227 minutes)</time_frame>
    <description>Time to meaningful pain relief was evaluated using the 2 stopwatch method and is defined as the time when the participant stops the second stopwatch. If it was not stopped time was censored at the time that the second stopwatch was stopped or the time of the second dose or the time that rescue medication was used whichever came first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Using Rescue Medication for Pain</measure>
    <time_frame>From Time 0 (first dose of study drug) up to 48 hours</time_frame>
    <description>The percentage of participants who needed to take an alternate medication for pain relief during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Use of Rescue Medication for Pain</measure>
    <time_frame>From Time 0 to time of first use of rescue medication (up to 280 minutes)</time_frame>
    <description>Time to first use of rescue medication is the time from Time 0 (time of administration of the first dose of study drug) to the first use of rescue medication. If rescue medication was not taken the time was censored at the time of the last pain assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Use of Rescue Medication Over 0 to 24 Hours and 0 to 48 Hours</measure>
    <time_frame>Over 24 and 48 hours after Time 0 (first dose of study drug)</time_frame>
    <description>Total use of rescue medication is defined as the number of times a participant took rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant's Global Evaluation of Study Drug</measure>
    <time_frame>End of treatment (Day 3) or early termination</time_frame>
    <description>Global evaluation of study drug was completed at the end of treatment (Day 3) or before early termination if a participant discontinued early. Participants were asked to provide an overall rating of their study medication in controlling pain on a 5-point NRS, where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent. The percentage of participants with scores in each pain relief category are reported.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">322</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Buprenorphine 0.5 mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received buprenorphine 0.5 mg sublingual (under the tongue) spray three times daily (TID) for two days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine 0.25 mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine 0.125 mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo-matching buprenorphine sublingual spray TID for two days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Buprenorphine sublingual spray delivered via single 100 μL spray</description>
    <arm_group_label>Buprenorphine 0.5 mg TID</arm_group_label>
    <arm_group_label>Buprenorphine 0.25 mg TID</arm_group_label>
    <arm_group_label>Buprenorphine 0.125 mg TID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets protocol-specified criteria for qualification and contraception

          -  Willing and able to remain confined in the study unit for the entire duration of each
             treatment period and comply with restrictions related food, drink and medications

          -  Voluntarily consents to participate and provides written informed consent prior to any
             protocol-specific procedures

        Exclusion Criteria:

          -  History or current use of over-the-counter medications, dietary supplements, or drugs
             (including nicotine and alcohol) outside protocol-specified parameters

          -  Signs, symptoms or history of any condition that, per protocol or in the opinion of
             the investigator, might compromise:

               1. the safety or well-being of the participant or study staff;

               2. the safety or well-being of the participant's offspring (such as through
                  pregnancy or breast-feeding);

               3. the analysis of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni DeCastro</last_name>
    <role>Study Director</role>
    <affiliation>INSYS Therapeutics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Research Group</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2015</study_first_posted>
  <results_first_submitted>June 1, 2017</results_first_submitted>
  <results_first_submitted_qc>August 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 14, 2017</results_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-Surgical Pain</keyword>
  <keyword>Bunionectomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
        </group>
        <group group_id="P2">
          <title>Buprenorphine 0.5 mg TID</title>
          <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
        </group>
        <group group_id="P3">
          <title>Buprenorphine 0.25 mg TID</title>
          <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
        </group>
        <group group_id="P4">
          <title>Buprenorphine 0.125 mg TID</title>
          <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population included all participants who were treated with the study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
        </group>
        <group group_id="B2">
          <title>Buprenorphine 0.5 mg TID</title>
          <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
        </group>
        <group group_id="B3">
          <title>Buprenorphine 0.25 mg TID</title>
          <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
        </group>
        <group group_id="B4">
          <title>Buprenorphine 0.125 mg TID</title>
          <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="82"/>
            <count group_id="B5" value="322"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.3" spread="14.55"/>
                    <measurement group_id="B2" value="43.7" spread="14.17"/>
                    <measurement group_id="B3" value="45.6" spread="11.78"/>
                    <measurement group_id="B4" value="48.4" spread="11.75"/>
                    <measurement group_id="B5" value="45.7" spread="13.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="254"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numeric Rating Scale (NRS) Summed Pain Intensity Difference (SPID) Over 0 to 48 Hours After Time 0 (NRS SPID-48)</title>
        <description>Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug) and at multiple time points up to 48 hours after Time 0 (administration of first dose of study drug). Pain intensity difference is calculated by subtracting the pain intensity at each time point from the pain intensity at Time 0. The SPID scores are the sum of the differences at each time point multiplied by the duration in hours since the previous time point. Positive numbers indicate a reduction in pain [maximum(max)=10 at each time point], and negative numbers indicate an increase in pain [minimum(min)=-10 at each time point]. The overall min and max are -10 and 10 times the number of hours specified; SPID-48 range is -480 to 480. The NRS SPID-48 was analyzed using an analysis of covariance (ANCOVA) model, which included treatment and site as main effects and Baseline pain intensity as the covariate.</description>
        <time_frame>Baseline and 0 to 48 hours after Time 0</time_frame>
        <population>All randomized participants from the Intent-to-Treat (ITT) Population who did not have missing SPID-48 values. Missing SPID-48 data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine 0.5 mg TID</title>
            <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine 0.25 mg TID</title>
            <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 0.125 mg TID</title>
            <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Numeric Rating Scale (NRS) Summed Pain Intensity Difference (SPID) Over 0 to 48 Hours After Time 0 (NRS SPID-48)</title>
          <description>Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug) and at multiple time points up to 48 hours after Time 0 (administration of first dose of study drug). Pain intensity difference is calculated by subtracting the pain intensity at each time point from the pain intensity at Time 0. The SPID scores are the sum of the differences at each time point multiplied by the duration in hours since the previous time point. Positive numbers indicate a reduction in pain [maximum(max)=10 at each time point], and negative numbers indicate an increase in pain [minimum(min)=-10 at each time point]. The overall min and max are -10 and 10 times the number of hours specified; SPID-48 range is -480 to 480. The NRS SPID-48 was analyzed using an analysis of covariance (ANCOVA) model, which included treatment and site as main effects and Baseline pain intensity as the covariate.</description>
          <population>All randomized participants from the Intent-to-Treat (ITT) Population who did not have missing SPID-48 values. Missing SPID-48 data were not imputed.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.40" spread="10.109"/>
                    <measurement group_id="O2" value="171.33" spread="10.316"/>
                    <measurement group_id="O3" value="125.58" spread="10.101"/>
                    <measurement group_id="O4" value="124.85" spread="9.944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The analysis included treatment and site as main effects and Baseline pain intensity as the covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>81.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.283</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>53.82</ci_lower_limit>
            <ci_upper_limit>110.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0108</p_value>
            <method>ANCOVA</method>
            <method_desc>The analysis included treatment and site as main effects and Baseline pain intensity as the covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>36.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.099</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.43</ci_lower_limit>
            <ci_upper_limit>63.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0120</p_value>
            <method>ANCOVA</method>
            <method_desc>The analysis included treatment and site as main effects and Baseline pain intensity as the covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>35.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.86</ci_lower_limit>
            <ci_upper_limit>63.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NRS Mean Pain Intensity Difference (PID) at 4, 8, 24 and 48 Hours After Time 0</title>
        <description>Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug administration) and at multiple time points up to 48 hours after Time 0 (time of administration of the first dose of study drug). NRS PID is defined as the difference in pain at each scheduled timepoint relative to Baseline (PID=pain intensity at baseline – pain intensity at time point). A higher value of NRS PID score indicates a higher decrease in pain from Baseline.</description>
        <time_frame>Baseline and 4, 8, 24 and 48 hours after Time 0</time_frame>
        <population>All randomized participants from the ITT Population with data available at each timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine 0.5 mg TID</title>
            <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine 0.25 mg TID</title>
            <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 0.125 mg TID</title>
            <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>NRS Mean Pain Intensity Difference (PID) at 4, 8, 24 and 48 Hours After Time 0</title>
          <description>Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug administration) and at multiple time points up to 48 hours after Time 0 (time of administration of the first dose of study drug). NRS PID is defined as the difference in pain at each scheduled timepoint relative to Baseline (PID=pain intensity at baseline – pain intensity at time point). A higher value of NRS PID score indicates a higher decrease in pain from Baseline.</description>
          <population>All randomized participants from the ITT Population with data available at each timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.13"/>
                    <measurement group_id="O2" value="2.6" spread="3.26"/>
                    <measurement group_id="O3" value="0.9" spread="3.14"/>
                    <measurement group_id="O4" value="1.1" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="2.10"/>
                    <measurement group_id="O2" value="2.5" spread="3.06"/>
                    <measurement group_id="O3" value="1.2" spread="2.78"/>
                    <measurement group_id="O4" value="0.7" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="2.59"/>
                    <measurement group_id="O2" value="4.0" spread="2.64"/>
                    <measurement group_id="O3" value="3.0" spread="2.72"/>
                    <measurement group_id="O4" value="3.2" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="2.60"/>
                    <measurement group_id="O2" value="4.9" spread="2.33"/>
                    <measurement group_id="O3" value="3.5" spread="3.00"/>
                    <measurement group_id="O4" value="4.1" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NRS Mean Pain Intensity Score at 4, 8, 24 and 48 Hours After Time 0</title>
        <description>Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug administration) and at multiple time points up to 48 hours after Time 0 (time of administration of the first dose of study drug). A lower value indicates improvement in pain.</description>
        <time_frame>4, 8, 24 and 48 hours after Time 0</time_frame>
        <population>All randomized participants from the ITT Population with data available at each timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine 0.5 mg TID</title>
            <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine 0.25 mg TID</title>
            <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 0.125 mg TID</title>
            <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>NRS Mean Pain Intensity Score at 4, 8, 24 and 48 Hours After Time 0</title>
          <description>Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug administration) and at multiple time points up to 48 hours after Time 0 (time of administration of the first dose of study drug). A lower value indicates improvement in pain.</description>
          <population>All randomized participants from the ITT Population with data available at each timepoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="2.45"/>
                    <measurement group_id="O2" value="4.1" spread="3.46"/>
                    <measurement group_id="O3" value="5.5" spread="3.24"/>
                    <measurement group_id="O4" value="5.6" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="2.51"/>
                    <measurement group_id="O2" value="4.2" spread="2.76"/>
                    <measurement group_id="O3" value="5.1" spread="2.75"/>
                    <measurement group_id="O4" value="5.9" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2.67"/>
                    <measurement group_id="O2" value="2.7" spread="2.39"/>
                    <measurement group_id="O3" value="3.4" spread="2.55"/>
                    <measurement group_id="O4" value="3.4" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.60"/>
                    <measurement group_id="O2" value="1.9" spread="1.95"/>
                    <measurement group_id="O3" value="2.8" spread="2.65"/>
                    <measurement group_id="O4" value="2.6" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NRS SPID Over 4 Hours (SPID-4), 8 Hours (SPID-8) and 24 Hours (SPID-24) After Time 0</title>
        <description>Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug) and at multiple time points up to 48 hours after Time 0 (administration of first dose of study drug). Pain intensity difference is calculated by subtracting the pain intensity at each time point from the pain intensity at Time 0. The SPID scores are the sum of the differences at each time point multiplied by the duration in hours since the previous time point. Positive numbers indicate a reduction in pain [max=10 at each time point] and negative numbers indicate an increase in pain [min=-10 at each time point]. The overall min and max are -10 and 10 times the number of hours specified: SPID-4=(-40 to 40), SPID-8=(-80 to 80) and SPID-24=(-240 to 240). The NRS SPID-4, 8 and 24 were analyzed using an ANCOVA model which included treatment and site as main effects and Baseline pain intensity as the covariate.</description>
        <time_frame>Baseline and 0 to 4, 0 to 8 and 0 to 24 hours after Time 0</time_frame>
        <population>All randomized participants from the Intent-to-Treat (ITT) Population who did not have missing SPID values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine 0.5 mg TID</title>
            <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine 0.25 mg TID</title>
            <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 0.125 mg TID</title>
            <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>NRS SPID Over 4 Hours (SPID-4), 8 Hours (SPID-8) and 24 Hours (SPID-24) After Time 0</title>
          <description>Pain intensity was assessed by the participant using an 11-point NRS from 0=no pain to 10=worst possible pain. Pain intensity scores were collected at Baseline (prior to study drug) and at multiple time points up to 48 hours after Time 0 (administration of first dose of study drug). Pain intensity difference is calculated by subtracting the pain intensity at each time point from the pain intensity at Time 0. The SPID scores are the sum of the differences at each time point multiplied by the duration in hours since the previous time point. Positive numbers indicate a reduction in pain [max=10 at each time point] and negative numbers indicate an increase in pain [min=-10 at each time point]. The overall min and max are -10 and 10 times the number of hours specified: SPID-4=(-40 to 40), SPID-8=(-80 to 80) and SPID-24=(-240 to 240). The NRS SPID-4, 8 and 24 were analyzed using an ANCOVA model which included treatment and site as main effects and Baseline pain intensity as the covariate.</description>
          <population>All randomized participants from the Intent-to-Treat (ITT) Population who did not have missing SPID values.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SPID-4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="1.036"/>
                    <measurement group_id="O2" value="7.70" spread="1.013"/>
                    <measurement group_id="O3" value="3.67" spread="1.023"/>
                    <measurement group_id="O4" value="3.74" spread="1.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="1.851"/>
                    <measurement group_id="O2" value="17.57" spread="1.835"/>
                    <measurement group_id="O3" value="8.26" spread="1.843"/>
                    <measurement group_id="O4" value="7.08" spread="1.837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID-24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.16" spread="5.001"/>
                    <measurement group_id="O2" value="75.67" spread="5.066"/>
                    <measurement group_id="O3" value="48.85" spread="4.962"/>
                    <measurement group_id="O4" value="44.17" spread="4.920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Pain Relief (TOTPAR) Over 4, 8, 24 and 48 Hours After Time 0</title>
        <description>TOTPAR was assessed by the participant using a 5-point NRS (0=no relief, 1=a little, 2=some, 3=a lot, 4=complete relief). TOTPAR scores were collected at Baseline (prior to study drug) and at multiple time points up to 48 hours after Time 0 (first dose of study drug). The TOTPAR scores are the sum of the pain relief at each time point multiplied by the duration in hours since the previous time point. Larger positive numbers indicate more pain relief (maximum=4 at each time point) and smaller positive numbers indicate less pain relief (minimum=0 at each time point). The overall minimum is 0 for each variable and the overall maximum is 4 times the number of hours specified for the variable: TOTPAR-4=(0 to 16), TOTPAR-8=(0 to 32), TOTPAR-24=(0 to 96) and TOTPAR-48=(0 to 192). TOTPAR-4, TOTPAR-8, TOTPAR-24 and TOTPAR-48 were analyzed using an ANCOVA model with factors for treatment, site and baseline pain intensity.</description>
        <time_frame>4, 8, 24 and 48 hours after Time 0</time_frame>
        <population>All randomized participants from the ITT Population with data available at each timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine 0.5 mg TID</title>
            <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine 0.25 mg TID</title>
            <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 0.125 mg TID</title>
            <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Pain Relief (TOTPAR) Over 4, 8, 24 and 48 Hours After Time 0</title>
          <description>TOTPAR was assessed by the participant using a 5-point NRS (0=no relief, 1=a little, 2=some, 3=a lot, 4=complete relief). TOTPAR scores were collected at Baseline (prior to study drug) and at multiple time points up to 48 hours after Time 0 (first dose of study drug). The TOTPAR scores are the sum of the pain relief at each time point multiplied by the duration in hours since the previous time point. Larger positive numbers indicate more pain relief (maximum=4 at each time point) and smaller positive numbers indicate less pain relief (minimum=0 at each time point). The overall minimum is 0 for each variable and the overall maximum is 4 times the number of hours specified for the variable: TOTPAR-4=(0 to 16), TOTPAR-8=(0 to 32), TOTPAR-24=(0 to 96) and TOTPAR-48=(0 to 192). TOTPAR-4, TOTPAR-8, TOTPAR-24 and TOTPAR-48 were analyzed using an ANCOVA model with factors for treatment, site and baseline pain intensity.</description>
          <population>All randomized participants from the ITT Population with data available at each timepoint.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TOTPAR-4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="0.467"/>
                    <measurement group_id="O2" value="6.23" spread="0.457"/>
                    <measurement group_id="O3" value="4.07" spread="0.461"/>
                    <measurement group_id="O4" value="4.38" spread="0.460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TOTPAR-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" spread="0.848"/>
                    <measurement group_id="O2" value="13.85" spread="0.841"/>
                    <measurement group_id="O3" value="9.22" spread="0.845"/>
                    <measurement group_id="O4" value="8.95" spread="0.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TOTPAR-24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.33" spread="2.304"/>
                    <measurement group_id="O2" value="53.30" spread="2.334"/>
                    <measurement group_id="O3" value="40.50" spread="2.286"/>
                    <measurement group_id="O4" value="40.45" spread="2.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TOTPAR-48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.88" spread="4.684"/>
                    <measurement group_id="O2" value="118.12" spread="4.780"/>
                    <measurement group_id="O3" value="95.73" spread="4.680"/>
                    <measurement group_id="O4" value="100.15" spread="4.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Analgesia</title>
        <description>Time to onset of analgesia was measured as time to first perceptible pain relief confirmed by meaningful pain relief using the 2-stopwatch method. The study staff started 2 stopwatches as soon as the first dose of study drug was administered. Each participant was instructed to stop the first stopwatch when he or she experienced any perceptible pain relief and the second stopwatch when he or she experienced pain relief that was meaningful to them. If the second stopwatch was not stopped, time was censored at the time of the second dose of study drug or the use of rescue medication, whichever came first. If both stopwatches were not stopped time was censored at the time of the second dose of study drug or the use of rescue medication whichever came first. Time to onset of analgesia was defined as the time when the first stopwatch was stopped given that the second stopwatch is stopped.</description>
        <time_frame>From Time 0 (first dose of study drug) to time of confirmed meaningful pain relief (up to 64 minutes)</time_frame>
        <population>All randomized participants from the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine 0.5 mg TID</title>
            <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine 0.25 mg TID</title>
            <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 0.125 mg TID</title>
            <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Analgesia</title>
          <description>Time to onset of analgesia was measured as time to first perceptible pain relief confirmed by meaningful pain relief using the 2-stopwatch method. The study staff started 2 stopwatches as soon as the first dose of study drug was administered. Each participant was instructed to stop the first stopwatch when he or she experienced any perceptible pain relief and the second stopwatch when he or she experienced pain relief that was meaningful to them. If the second stopwatch was not stopped, time was censored at the time of the second dose of study drug or the use of rescue medication, whichever came first. If both stopwatches were not stopped time was censored at the time of the second dose of study drug or the use of rescue medication whichever came first. Time to onset of analgesia was defined as the time when the first stopwatch was stopped given that the second stopwatch is stopped.</description>
          <population>All randomized participants from the ITT Population.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not estimable because less than 50% of participants achieved onset</measurement>
                    <measurement group_id="O2" value="43.0" lower_limit="21.0" upper_limit="64.0"/>
                    <measurement group_id="O3" value="NA" lower_limit="43.0">Not estimable because less than 50% of participants achieved onset</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="41.0">Not estimable because less than 50% of participants achieved onset</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Scores in Each Pain Relief Category at 4, 8, 24 and 48 Hours After Time 0</title>
        <description>Pain relief was assessed by the participant using a 5-point NRS (0=no relief, 1=a little, 2=some, 3=a lot, 4=complete relief). The percentage of participants with scores in each pain relief category are reported. Missing values were imputed.</description>
        <time_frame>4, 8, 24 and 48 hours after Time 0 (first dose of study drug)</time_frame>
        <population>All randomized participants from the ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine 0.5 mg TID</title>
            <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine 0.25 mg TID</title>
            <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 0.125 mg TID</title>
            <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Scores in Each Pain Relief Category at 4, 8, 24 and 48 Hours After Time 0</title>
          <description>Pain relief was assessed by the participant using a 5-point NRS (0=no relief, 1=a little, 2=some, 3=a lot, 4=complete relief). The percentage of participants with scores in each pain relief category are reported. Missing values were imputed.</description>
          <population>All randomized participants from the ITT Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 Hours - No relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8"/>
                    <measurement group_id="O2" value="24.7"/>
                    <measurement group_id="O3" value="43.8"/>
                    <measurement group_id="O4" value="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hours - A little relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5"/>
                    <measurement group_id="O2" value="16.0"/>
                    <measurement group_id="O3" value="22.5"/>
                    <measurement group_id="O4" value="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hours - Some relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                    <measurement group_id="O2" value="21.0"/>
                    <measurement group_id="O3" value="13.8"/>
                    <measurement group_id="O4" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hours - A lot of relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="19.8"/>
                    <measurement group_id="O3" value="13.8"/>
                    <measurement group_id="O4" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hours - Complete relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="18.5"/>
                    <measurement group_id="O3" value="6.3"/>
                    <measurement group_id="O4" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Hours - No relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0"/>
                    <measurement group_id="O2" value="18.5"/>
                    <measurement group_id="O3" value="32.5"/>
                    <measurement group_id="O4" value="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Hours - A little relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4"/>
                    <measurement group_id="O2" value="14.8"/>
                    <measurement group_id="O3" value="22.5"/>
                    <measurement group_id="O4" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Hours - Some relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                    <measurement group_id="O2" value="27.2"/>
                    <measurement group_id="O3" value="21.3"/>
                    <measurement group_id="O4" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Hours - A lot of relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1"/>
                    <measurement group_id="O2" value="23.5"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Hours - Complete relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="12.3"/>
                    <measurement group_id="O3" value="8.8"/>
                    <measurement group_id="O4" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours - No relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3"/>
                    <measurement group_id="O2" value="6.2"/>
                    <measurement group_id="O3" value="7.5"/>
                    <measurement group_id="O4" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours - A little relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="21.3"/>
                    <measurement group_id="O4" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours - Some relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1"/>
                    <measurement group_id="O2" value="23.5"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours - A lot of relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7"/>
                    <measurement group_id="O2" value="38.3"/>
                    <measurement group_id="O3" value="26.3"/>
                    <measurement group_id="O4" value="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours - Complete relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="19.8"/>
                    <measurement group_id="O3" value="15.0"/>
                    <measurement group_id="O4" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours - No relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="8.8"/>
                    <measurement group_id="O4" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours - A little relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                    <measurement group_id="O2" value="8.6"/>
                    <measurement group_id="O3" value="11.3"/>
                    <measurement group_id="O4" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours - Some relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3"/>
                    <measurement group_id="O2" value="12.3"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours - A lot of relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="38.3"/>
                    <measurement group_id="O3" value="32.5"/>
                    <measurement group_id="O4" value="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hours - Complete relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2"/>
                    <measurement group_id="O2" value="27.2"/>
                    <measurement group_id="O3" value="21.3"/>
                    <measurement group_id="O4" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Peak Scores in Each Pain Relief Category</title>
        <description>Peak pain relief is the highest value of pain relief experienced during the study. Pain relief was assessed by the participant using a 5-point NRS (0=no relief, 1=a little, 2=some, 3=a lot, 4=complete relief). The percentage of participants with peak scores in each pain relief category are reported.</description>
        <time_frame>From Time 0 (first dose of study drug) up to 48 hours</time_frame>
        <population>All randomized participants from the ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine 0.5 mg TID</title>
            <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine 0.25 mg TID</title>
            <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 0.125 mg TID</title>
            <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Peak Scores in Each Pain Relief Category</title>
          <description>Peak pain relief is the highest value of pain relief experienced during the study. Pain relief was assessed by the participant using a 5-point NRS (0=no relief, 1=a little, 2=some, 3=a lot, 4=complete relief). The percentage of participants with peak scores in each pain relief category are reported.</description>
          <population>All randomized participants from the ITT Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.3"/>
                    <measurement group_id="O4" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="3.8"/>
                    <measurement group_id="O4" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="9.9"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A lot of relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7"/>
                    <measurement group_id="O2" value="42.0"/>
                    <measurement group_id="O3" value="46.3"/>
                    <measurement group_id="O4" value="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6"/>
                    <measurement group_id="O2" value="45.7"/>
                    <measurement group_id="O3" value="36.3"/>
                    <measurement group_id="O4" value="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A lot of relief + Complete relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3"/>
                    <measurement group_id="O2" value="87.7"/>
                    <measurement group_id="O3" value="82.6"/>
                    <measurement group_id="O4" value="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak Pain Relief</title>
        <description>Time to peak pain relief is the time to the highest value of pain relief experienced during the study. Pain relief was assessed by the participant using a 5-point NRS (0=no relief, 1=a little, 2=some, 3=a lot, 4=complete relief). If no pain relief was observed, then the time was censored at the time of the last pain assessment.</description>
        <time_frame>From Time 0 (first dose of study drug) to time of peak pain relief (up to 1437 minutes)</time_frame>
        <population>All randomized participants from the ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine 0.5 mg TID</title>
            <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine 0.25 mg TID</title>
            <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 0.125 mg TID</title>
            <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Pain Relief</title>
          <description>Time to peak pain relief is the time to the highest value of pain relief experienced during the study. Pain relief was assessed by the participant using a 5-point NRS (0=no relief, 1=a little, 2=some, 3=a lot, 4=complete relief). If no pain relief was observed, then the time was censored at the time of the last pain assessment.</description>
          <population>All randomized participants from the ITT Population</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1200.0" lower_limit="720.0" upper_limit="1200.0"/>
                    <measurement group_id="O2" value="360.0" lower_limit="181.0" upper_limit="719.0"/>
                    <measurement group_id="O3" value="720.0" lower_limit="420.0" upper_limit="960.0"/>
                    <measurement group_id="O4" value="1200.0" lower_limit="720.0" upper_limit="1437.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Perceptible Pain Relief</title>
        <description>Time to first perceptible pain relief was evaluated using the 2 stopwatch method and is defined as the time when the participant stops the first stopwatch. If it was not stopped time was censored at the time that the second stopwatch was stopped or the time of the second dose or the time that rescue medication was used whichever came first.</description>
        <time_frame>From Time 0 (first dose of study drug) to time of first perceptible pain relief (up to 83 minutes)</time_frame>
        <population>All randomized participants from the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine 0.5 mg TID</title>
            <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine 0.25 mg TID</title>
            <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 0.125 mg TID</title>
            <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Perceptible Pain Relief</title>
          <description>Time to first perceptible pain relief was evaluated using the 2 stopwatch method and is defined as the time when the participant stops the first stopwatch. If it was not stopped time was censored at the time that the second stopwatch was stopped or the time of the second dose or the time that rescue medication was used whichever came first.</description>
          <population>All randomized participants from the ITT Population.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" lower_limit="6.0" upper_limit="83.0"/>
                    <measurement group_id="O2" value="23.0" lower_limit="10.0" upper_limit="43.0"/>
                    <measurement group_id="O3" value="15.0" lower_limit="11.0" upper_limit="42.0"/>
                    <measurement group_id="O4" value="27.0" lower_limit="14.0" upper_limit="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Meaningful Pain Relief</title>
        <description>Time to meaningful pain relief was evaluated using the 2 stopwatch method and is defined as the time when the participant stops the second stopwatch. If it was not stopped time was censored at the time that the second stopwatch was stopped or the time of the second dose or the time that rescue medication was used whichever came first.</description>
        <time_frame>From Time 0 (first dose of study drug) to time of meaningful pain relief (up to 227 minutes)</time_frame>
        <population>All randomized participants from the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine 0.5 mg TID</title>
            <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine 0.25 mg TID</title>
            <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 0.125 mg TID</title>
            <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Meaningful Pain Relief</title>
          <description>Time to meaningful pain relief was evaluated using the 2 stopwatch method and is defined as the time when the participant stops the second stopwatch. If it was not stopped time was censored at the time that the second stopwatch was stopped or the time of the second dose or the time that rescue medication was used whichever came first.</description>
          <population>All randomized participants from the ITT Population.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238.0" lower_limit="121.0">Not estimable because less than 50% of participants achieved meaningful pain relief</measurement>
                    <measurement group_id="O2" value="92.0" lower_limit="79.0" upper_limit="120.0"/>
                    <measurement group_id="O3" value="122.0" lower_limit="90.0" upper_limit="227.0"/>
                    <measurement group_id="O4" value="166.0" lower_limit="87.0" upper_limit="240.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Using Rescue Medication for Pain</title>
        <description>The percentage of participants who needed to take an alternate medication for pain relief during the treatment period.</description>
        <time_frame>From Time 0 (first dose of study drug) up to 48 hours</time_frame>
        <population>All randomized participants from the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine 0.5 mg TID</title>
            <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine 0.25 mg TID</title>
            <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 0.125 mg TID</title>
            <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Using Rescue Medication for Pain</title>
          <description>The percentage of participants who needed to take an alternate medication for pain relief during the treatment period.</description>
          <population>All randomized participants from the ITT Population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5"/>
                    <measurement group_id="O2" value="55.6"/>
                    <measurement group_id="O3" value="87.5"/>
                    <measurement group_id="O4" value="87.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Use of Rescue Medication for Pain</title>
        <description>Time to first use of rescue medication is the time from Time 0 (time of administration of the first dose of study drug) to the first use of rescue medication. If rescue medication was not taken the time was censored at the time of the last pain assessment.</description>
        <time_frame>From Time 0 to time of first use of rescue medication (up to 280 minutes)</time_frame>
        <population>All randomized participants from the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine 0.5 mg TID</title>
            <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine 0.25 mg TID</title>
            <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 0.125 mg TID</title>
            <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Use of Rescue Medication for Pain</title>
          <description>Time to first use of rescue medication is the time from Time 0 (time of administration of the first dose of study drug) to the first use of rescue medication. If rescue medication was not taken the time was censored at the time of the last pain assessment.</description>
          <population>All randomized participants from the ITT Population.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.0" lower_limit="77.0" upper_limit="125.0"/>
                    <measurement group_id="O2" value="937.0" lower_limit="349.0">Not estimable because too few participants used rescue medication</measurement>
                    <measurement group_id="O3" value="219.5" lower_limit="105.0" upper_limit="260.0"/>
                    <measurement group_id="O4" value="193.0" lower_limit="92.0" upper_limit="280.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Use of Rescue Medication Over 0 to 24 Hours and 0 to 48 Hours</title>
        <description>Total use of rescue medication is defined as the number of times a participant took rescue medication.</description>
        <time_frame>Over 24 and 48 hours after Time 0 (first dose of study drug)</time_frame>
        <population>All randomized participants from the ITT Population who used rescue medication during the specified time intervals.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine 0.5 mg TID</title>
            <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine 0.25 mg TID</title>
            <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 0.125 mg TID</title>
            <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Use of Rescue Medication Over 0 to 24 Hours and 0 to 48 Hours</title>
          <description>Total use of rescue medication is defined as the number of times a participant took rescue medication.</description>
          <population>All randomized participants from the ITT Population who used rescue medication during the specified time intervals.</population>
          <units>number of uses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-24 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.98"/>
                    <measurement group_id="O2" value="2.2" spread="1.69"/>
                    <measurement group_id="O3" value="2.6" spread="1.62"/>
                    <measurement group_id="O4" value="2.9" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-48 Hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="3.60"/>
                    <measurement group_id="O2" value="2.9" spread="2.81"/>
                    <measurement group_id="O3" value="3.7" spread="2.68"/>
                    <measurement group_id="O4" value="3.9" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant's Global Evaluation of Study Drug</title>
        <description>Global evaluation of study drug was completed at the end of treatment (Day 3) or before early termination if a participant discontinued early. Participants were asked to provide an overall rating of their study medication in controlling pain on a 5-point NRS, where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent. The percentage of participants with scores in each pain relief category are reported.</description>
        <time_frame>End of treatment (Day 3) or early termination</time_frame>
        <population>All randomized participants from the ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine 0.5 mg TID</title>
            <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine 0.25 mg TID</title>
            <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
          </group>
          <group group_id="O4">
            <title>Buprenorphine 0.125 mg TID</title>
            <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant's Global Evaluation of Study Drug</title>
          <description>Global evaluation of study drug was completed at the end of treatment (Day 3) or before early termination if a participant discontinued early. Participants were asked to provide an overall rating of their study medication in controlling pain on a 5-point NRS, where 0=poor, 1=fair, 2=good, 3=very good, and 4=excellent. The percentage of participants with scores in each pain relief category are reported.</description>
          <population>All randomized participants from the ITT Population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="5.0"/>
                    <measurement group_id="O4" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3"/>
                    <measurement group_id="O2" value="7.4"/>
                    <measurement group_id="O3" value="16.3"/>
                    <measurement group_id="O4" value="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="16.0"/>
                    <measurement group_id="O3" value="26.3"/>
                    <measurement group_id="O4" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="32.1"/>
                    <measurement group_id="O3" value="30.0"/>
                    <measurement group_id="O4" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1"/>
                    <measurement group_id="O2" value="38.3"/>
                    <measurement group_id="O3" value="18.8"/>
                    <measurement group_id="O4" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug to the Follow-up visit (up to 9 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo-matching buprenorphine sublingual (under the tongue) spray TID for two days.</description>
        </group>
        <group group_id="E2">
          <title>Buprenorphine 0.5 mg TID</title>
          <description>Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) for two days.</description>
        </group>
        <group group_id="E3">
          <title>Buprenorphine 0.25 mg TID</title>
          <description>Participants received buprenorphine 0.25 mg sublingual spray TID for two days.</description>
        </group>
        <group group_id="E4">
          <title>Buprenorphine 0.125 mg TID</title>
          <description>Participants received buprenorphine 0.125 mg sublingual spray TID for two days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Development</name_or_title>
      <organization>Insys Therapeutics, Inc.</organization>
      <phone>480-500-3105</phone>
      <email>gdecastro@insysrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

